Benefits of Testosterone Replacement Therapy in Hypogonadal Males

References

1. 1.↵
   1. Ross A,
   2. Bhasin S

   . Hypogonadism: its prevalence and diagnosis. Urol Clin North Am 2016;43:163–76.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Kaufman JM

   . Diagnosis of hypogonadism in ageing men. Rev Endocr Metab Disord 2022;23:1139–50.

   OpenUrlPubMed
3. 3.↵
   1. Giagulli VA,
   2. Castellana M,
   3. Lisco G,
   4. et al

   . Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology 2020;8:1628–41.

   OpenUrlPubMed
4. 4.↵
   1. Al-Sharefi A,
   2. Quinton R

   . Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul) 2020;35:526–40.

   OpenUrlPubMed
5. 5.↵
   1. Locke JA,
   2. Flannigan R,
   3. Günther OP,
   4. et al

   . Testosterone therapy: prescribing and monitoring patterns of practice in British Columbia. Can Urol Assoc J 2021;15:E110–E117.

   OpenUrlPubMed
6. 6.↵
   1. Baillargeon J,
   2. Kuo YF,
   3. Westra JR,
   4. et al

   . Testosterone prescribing in the United States, 2002-2016. JAMA 2018;320:200–2.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Vigen R,
   2. O'Donnell CI,
   3. Barón AE,
   4. et al

   . Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829–36.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Bandari J,
   2. Ayyash OM,
   3. Emery SL,
   4. et al

   . Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus 2017;3:395–402.

   OpenUrlPubMed
9. 9.↵
   1. Muraleedharan V,
   2. Hugh Jones T

   . Testosterone and mortality. Clin Endocrinol (Oxf) 2014;81:477–87.

   OpenUrlPubMed
10. 10.↵
    1. Araujo AB,
    2. Dixon JM,
    3. Suarez EA,
    4. et al

    . Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007–19.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Sharma R,
    2. Oni OA,
    3. Gupta K,
    4. et al

    . Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc 2017;6:e004880.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Heeringa J,
    2. van der Kuip DAM,
    3. Hofman A,
    4. et al

    . Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–53.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Berger D,
    2. Folsom AR,
    3. Schreiner PJ,
    4. et al

    . Plasma total testosterone and risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. Maturitas 2019;125:5–10.

    OpenUrlPubMed
14. 14.↵
    1. Lincoff AM,
    2. Bhasin S,
    3. Flevaris P

    , TRAVERSE Study Investigatorset al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107–17.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Guzik A,
    2. Bushnell C

    . Stroke epidemiology and risk factor management. Continuum (Minneap Minn) 2017;23:15–39.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Yeap BB,
    2. Hyde Z,
    3. Almeida OP,
    4. et al

    . Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009;94:2353–9.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Jeppesen LL,
    2. Jørgensen HS,
    3. Nakayama H,
    4. et al

    . Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 1996;16:749–54.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Pollard TJ

    . The acute myocardial infarction. Prim Care 2000;27:631–49;vi.

    OpenUrlPubMed
19. 19.↵
    1. Kloner RA,
    2. Carson C,
    3. Dobs A,
    4. et al

    . Testosterone and cardiovascular disease. J Am Coll Cardiol 2016;67:545–57.

    OpenUrlFREE Full Text
20. 20.↵
    1. Huggins C,
    2. Hodges CV

    . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232–40.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Lenfant L,
    2. Leon P,
    3. Cancel-Tassin G,
    4. et al

    . Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol 2020;38:661–70.

    OpenUrlPubMed
22. 22.↵
    1. Debruyne FMJ,
    2. Behre HM,
    3. Roehrborn CG

    , RHYME Investigatorset al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int . 2017;119:216–24.

    OpenUrlPubMed
23. 23.↵
    1. Gore J,
    2. Rajfer J

    . Rising PSA during testosterone replacement therapy. Rev Urol 2004;6 Suppl 6:S41–S43.

    OpenUrl
24. 24.↵
    1. Murphy LR,
    2. Hill TP,
    3. Paul K,
    4. et al

    . Tenecteplase versus alteplase for acute stroke: mortality and bleeding complications. Ann Emerg Med 2023;82:720–8. Published online May 11S0196-0644.

    OpenUrlPubMed
25. 25.↵
    1. Shores MM,
    2. Smith NL,
    3. Forsberg CW,
    4. et al

    . Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–8.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Sharma R,
    2. Oni OA,
    3. Gupta K,
    4. et al

    . Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015;36:2706–15.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Fantus RJ,
    2. Chang C,
    3. Platz EA,
    4. et al

    . Serum total testosterone and premature mortality among men in the USA. Eur Urol Open Sci 2021;29:89–92.

    OpenUrlPubMed
28. 28.↵
    1. Go AS,
    2. Hylek EM,
    3. Phillips KA,
    4. et al

    . Prevalence of diagnosed atrial fibrillation in adults’ national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Magnani JW,
    2. Moser CB,
    3. Murabito JM,
    4. et al

    . Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ Arrhythm Electrophysiol 2014;7:307–12.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Tsuneda T,
    2. Yamashita T,
    3. Kato T,
    4. et al

    . Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol 2009;20:1055–60.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Svartberg J,
    2. von Mühlen D,
    3. Mathiesen E,
    4. et al

    . Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 2006;259:576–82.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Morgunov LY,
    2. Denisova IA,
    3. Rozhkova TI,
    4. et al

    . Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male 2020;23:71–80.

    OpenUrlPubMed
33. 33.↵
    1. Basaria S,
    2. Coviello AD,
    3. Travison TG,
    4. et al

    . Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–22.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Finkle WD,
    2. Greenland S,
    3. Ridgeway GK,
    4. et al

    . Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS ONE 2014;9:e85805.

    OpenUrlCrossRefPubMed
35. 35.↵
    Research C for DE and FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA. Published online February 9, 2019. Accessed September 19, 2023. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due.
36. 36.↵
    1. Corona G,
    2. Rastrelli G,
    3. Monami M,
    4. et al

    . Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011;165:687–701.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Baillargeon J,
    2. Urban RJ,
    3. Kuo YF,
    4. et al

    . Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014;48:1138–44.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Ramasamy R,
    2. Fisher ES,
    3. Schlegel PN

    . Testosterone replacement and prostate cancer. Indian J Urol 2012;28:123–8.

    OpenUrlPubMed
39. 39.↵
    1. Eisenberg ML

    . Testosterone replacement therapy and prostate cancer incidence. World J Mens Health 2015;33:125–9.

    OpenUrlPubMed
40. 40.↵
    1. Morgentaler A,
    2. Traish AM

    . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310–20.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Khera M,
    2. Bhattacharya RK,
    3. Blick G,
    4. et al

    . Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol 2011;186:1005–11.

    OpenUrlPubMed
42. 42.↵
    1. Surampudi PN,
    2. Wang C,
    3. Swerdloff R

    . Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012;2012:625434.

    OpenUrlPubMed
43. 43.↵
    1. Sellke N,
    2. Omil-Lima D,
    3. Sun HH,
    4. et al

    . Trends in testosterone prescription during the release of society guidelines. Int J Impot Res 2023;36:380–4. Published online May 2.

    OpenUrlPubMed